HCB101

PreclinicalSmall molecule

FFBD Biologics Limited

HCB101 is one of 80 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

HNSCCRecruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

HNSCCPreclinical

Recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

94 2

Erbitux

Lumakras

2 4

Innohep

Alnylam Pharmaceuticals

Phase 3

1 5

FOLFOX 2d

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 6

JMT101

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3

2 7

Oxaliplatin, /m2

Roche

Phase 3

1 8

Eylea

Regeneron

Preclinical

18 9

Leucovorin and 5-FU

AAkeso

Phase 3

2 10

Capecitabine, /m2

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

HNSCC

NCT07136545

Q1 2029

Phase 1/2Active, not recruiting

Patients With Advanced Solid Tumors

NCT06771622

Q4 2029

Phase 1Recruiting

Safety and Efficacy

NCT05892718

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Recruiting·—·Phase 1/2·NCT07204574·40 enrolled

Safety and Efficacy1 trial

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Recruiting·FFBD Biologics Limited·Phase 1·NCT05892718·80 enrolled

Patients With Advanced Solid Tumors1 trial

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

HNSCC1 trial

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

Recruiting·TTaipei Veterans General Hospital, Taiwan·Preclinical·NCT07136545·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HCB101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HCB101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HCB101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — FBD Biologics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFBD Biologics Limited

HCB101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2029

Q4 2029

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Safety and Efficacy1 trial

Patients With Advanced Solid Tumors1 trial

HNSCC1 trial

References

Drug Info

Quick Facts

Related News